{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:16:31Z","timestamp":1787498191511,"version":"build-2736575974"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":329,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015883","name":"Spanish Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015883","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2019-01059"],"award-info":[{"award-number":["2019-01059"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Heart and Lung Foundation","award":["#20190587"],"award-info":[{"award-number":["#20190587"]}]},{"name":"Westman Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,22]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is associated with high rates of cardiovascular events. We here explored whether the recently described triglycerides\u2013glucose index (TyG) predicted the incidence of major adverse cardiovascular events (MACE) in these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This observationa study was undertaken of 1142 persons with CKD and free from diabetes and 460 controls from the prospective NEFRONA study. The study exposure was the TyG index at cohort inclusion. The study outcome was MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and hospitalization for unstable angina). Covariates included demographics, comorbidities, lipid profile, renal function and glycaemic control. Cox regression models evaluated the association between TyG index and 4-point MACE in patients with CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TyG was higher [median 8.63 (interquartile range 8.32\u20138.95)] in patients with CKD compared with controls (P\u00a0&amp;lt;\u00a00.001). TyG increased across albuminuria categories but was similar for glomerular filtration rate categories among patients with CKD stages 3\u20135. During 46\u00a0\u00b1\u00a013\u00a0months of follow-up, 49 (4.3%) MACE were registered. TyG predicted the occurrence of MACE {hazard ratio (HR) 1.95 [95% confidence interval (CI) 1.11\u20133.40] per TyG unit increase; and HR 2.29 (95% CI 1.24\u20134.20] for TyG values above the median of 8.63 units}. Sensitivity analysis for subgroups of participants according to age, kidney function, body mass index and imaging evidence of atherosclerosis yielded similar results, as did adjusted analysis. Neither triglycerides nor glucose alone was associated with MACE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The TyG index is associated with the occurrence of major cardiovascular events in persons free from diabetes with non-dialysis dependent CKD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ckj\/sfac073","type":"journal-article","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T15:14:00Z","timestamp":1646752440000},"page":"1705-1712","source":"Crossref","is-referenced-by-count":25,"title":["Triglycerides\u2013glucose index and the risk of cardiovascular events in persons with non-diabetic chronic kidney disease"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5730-1929","authenticated-orcid":false,"given":"Borja","family":"Quiroga","sequence":"first","affiliation":[{"name":"IIS-La Princesa, Nephrology Department, Hospital Universitario de la Princesa , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz Ramos","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitario Infanta Leonor , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"S\u00e1nchez Horrillo","sequence":"additional","affiliation":[{"name":"IIS-La Princesa, Nephrology Department, Hospital Universitario de la Princesa , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-9523","authenticated-orcid":false,"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundaci\u00f3n Jimenez Diaz, School of Medicine, Universidad Aut\u00f3noma de Madrid, Fundaci\u00f3n Renal I\u00f1igo Alvarez de Toledo-IRSIN, REDinREN, Instituto de Investigaci\u00f3n Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Valdivielso","sequence":"additional","affiliation":[{"name":"Vascular and Renal Translational Research Group, UDETMA, REDinREN del ISCIII, IRBLleida , Lleida , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4763-2024","authenticated-orcid":false,"given":"Juan Jes\u00fas","family":"Carrero","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,3,10]]},"reference":[{"key":"2023020205114391400_bib1","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1053\/ajkd.2001.29275","article-title":"Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter","volume":"38","author":"Levin","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"2023020205114391400_bib2","first-page":"539","article-title":"Cardiovascular events and mortality in chronic kidney disease (stages I-IV)","volume":"33","author":"Quiroga","year":"2013","journal-title":"Nefrologia"},{"key":"2023020205114391400_bib3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet North Am Ed"},{"key":"2023020205114391400_bib4","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2023020205114391400_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","article-title":"An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients","volume":"23","author":"Bermudez-Lopez","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"2023020205114391400_bib6","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","article-title":"Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD","volume":"73","author":"Bajaj","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2023020205114391400_bib7","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2023020205114391400_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12933-021-01268-9","article-title":"Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies","volume":"20","author":"Ding","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023020205114391400_bib9","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s10157-019-01729-2","article-title":"Triglyceride-glucose index is a predictor of incident chronic kidney disease: a population-based longitudinal study","volume":"23","author":"Okamura","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2023020205114391400_bib10","doi-asserted-by":"crossref","first-page":"e212612","DOI":"10.1001\/jamanetworkopen.2021.2612","article-title":"The triglyceride\u2013glucose index and obesity-related risk of end-stage kidney disease in Austrian adults","volume":"4","author":"Fritz","year":"2021","journal-title":"JAMA Network Open"},{"key":"2023020205114391400_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1159\/000500979","article-title":"Triglyceride glucose index predicting cardiovascular mortality in Chinese initiating peritoneal dialysis: a cohort study","volume":"44","author":"Yan","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"2023020205114391400_bib12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"2023020205114391400_bib13","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1471-2369-15-168","article-title":"Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study","volume":"15","author":"Arroyo","year":"2014","journal-title":"BMC Nephrol"},{"key":"2023020205114391400_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/met.2008.0034","article-title":"The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects","volume":"6","author":"Simental-Mend\u00eda","year":"2008","journal-title":"Metab Syndr Relat Disord"},{"key":"2023020205114391400_bib15","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023020205114391400_bib16","first-page":"S1","article-title":". K\/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease","volume":"41","author":"K\/DOQI Group","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2023020205114391400_bib17","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2369-11-14","article-title":"Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study","volume":"11","author":"Junyent","year":"2010","journal-title":"BMC Nephrol"},{"key":"2023020205114391400_bib18","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/14728222.2017.1369961","article-title":"New perspectives on CKD-induced dyslipidemia","volume":"21","author":"Berm\u00fadez-L\u00f3pez","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"2023020205114391400_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000518456","article-title":"Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives","volume":"52","author":"Theofilis","year":"2021","journal-title":"Am J Nephrol"},{"key":"2023020205114391400_bib20","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1194\/jlr.P900003-JLR200","article-title":"Chronic kidney disease delays VLDL-apoB-100 particle catabolism: potential role of apolipoprotein C-III","volume":"50","author":"Chan","year":"2009","journal-title":"J Lipid Res"},{"key":"2023020205114391400_bib21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.07320619","article-title":"Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD","volume":"15","author":"Lamprea-Montealegre","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023020205114391400_bib22","first-page":"259","article-title":"KDIGO clinical practice guideline for lipid management in chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2023020205114391400_bib23","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.jacc.2017.10.024","article-title":"Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors","volume":"70","author":"Fern\u00e1ndez-Friera","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2023020205114391400_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nefroe.2017.11.016","article-title":"Beyond the traditional lipid parameters in chronic kidney disease. M\u00e1s all\u00e1 de los par\u00e1metros lip\u00eddicos tradicionales en la enfermedad renal cr\u00f3nica","volume":"38","author":"Berm\u00fadez-L\u00f3pez","year":"2018","journal-title":"Nefrolog\u00eda (English Edition)"},{"key":"2023020205114391400_bib25","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.hlc.2017.05.142","article-title":"The TyG index as a marker of subclinical atherosclerosis and arterial stiffness in lean and overweight postmenopausal women","volume":"27","author":"Lambrinoudaki","year":"2018","journal-title":"Heart Lung Circ"},{"key":"2023020205114391400_bib26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12933-021-01391-7","article-title":"Gender difference in the association between TyG index and subclinical atherosclerosis: results from the I-Lan Longitudinal Aging Study","volume":"20","author":"Lu","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2023020205114391400_bib27","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-6507.21.03465-5","article-title":"SGLT2 inhibitors improve plasma atherogenic biomarkers in patients with type 2 diabetes: a real world retrospective observational study","author":"Imre","year":"2021","journal-title":"Minerva Endocrinol"},{"key":"2023020205114391400_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet North Am Ed"},{"key":"2023020205114391400_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.atherosclerosis.2021.04.008","article-title":"Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe\/placebo in patients at high cardiovascular risk","volume":"326","author":"Ma","year":"2021","journal-title":"Atherosclerosis"},{"key":"2023020205114391400_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12944-020-01297-5","article-title":"Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression","volume":"19","author":"Masson","year":"2020","journal-title":"Lipids Health Dis"},{"key":"2023020205114391400_bib31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.numecd.2020.11.009","article-title":"Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: a single lipid center real-world experience","volume":"31","author":"Scicali","year":"2021","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfac073\/43705791\/sfac073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/9\/1705\/49039685\/sfac073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/15\/9\/1705\/49039685\/sfac073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:19:38Z","timestamp":1675297178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/15\/9\/1705\/6546217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,10]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,3,10]]},"published-print":{"date-parts":[[2022,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfac073","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9]]},"published":{"date-parts":[[2022,3,10]]}}}